CCM
ATRS

Carderock Capital Management’s Antares Pharma, Inc. ATRS Stock Holding History

Carderock Capital Management’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,000
Closed -$109K – 159
2021
Q2 		$109K Buy
+25,000
New +$102K 0.03% 79

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Carderock Capital Management's ATRS Position: Q3 2021 in Review

Carderock Capital Management sold out of Antares Pharma, Inc. (ATRS) in Q3 2021, closing a stake of 25,000 shares — an estimated $109K sold.

Carderock Capital Management first reported a position in ATRS in Q2 2021 and held it in 1 quarter. The position peaked at $109K in Q2 2021. 170 funds tracked by Wall St. Rank hold ATRS as of Q3 2021.

  • Carderock Capital Management reported no remaining Antares Pharma, Inc. position as of Q3 2021 after selling out during the quarter.
  • Carderock Capital Management sold 25,000 Antares Pharma, Inc. shares in Q3 2021, an estimated $109K.
  • Carderock Capital Management first reported a position in Antares Pharma, Inc. in Q2 2021 and held it in 1 quarter.
  • Carderock Capital Management's Antares Pharma, Inc. position peaked at $109K in Q2 2021.
  • 170 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2021.

Based on Carderock Capital Management's 13F filing for Q3 2021, filed 29 Oct 2021.